Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/hAj3UZjbHJ https://t.co/eQHjEgelRM

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/tZW3vNCl7T https://t.co/8IB3q3xNY6

Chronic Pain Management tools 1 Medication 2 Physical Therapy 3 Cognitive-Behavioral Therapy 4 Mindfulness Meditation 5 Acupuncture 6 Massage 7 Heat/Cold 8 TENS 9 Yoga/Tai Chi 10 Support groups https://t.co/hb6ACoS6Xn https://t.co/AZRM873J6Z

RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0U47rSH7KB https://t.co/SNy8Egw59z

Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome? https://t.co/5GNUZolPsz https://t.co/bIFKPjWBM0

Ultrasonography May Improve OA Pain Prediction Dr. Bella Mehta reports on POS0107 from EULAR 2023 in Milan, Italy. https://t.co/ZHBdWPWTys https://t.co/JLIScNVZGB

EULAR 2023 Lupus Highlights https://t.co/CGybJRjDDK https://t.co/2kkB1hX2J5

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective? The use of methotrextate with either bDMARDs, tsDMARDs or bsDMARDs was not shown to be cost effective, even though reduced disease activity and improved patient quality of life. Read more--https://t.co/4nBp0ML8Kl https://t.co/5YXCotHlYK

Cancer Risk From RA, Not the Drugs A large US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk. https://t.co/6yrc0TsT53 https://t.co/WRQzeFoR1Z

An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately given METFORMIN or Placebo. Cumulative incidence of long COVID at day 300 was 6.3% w/ metformin vs 10.4% w/ placebo (HR 0.59; HR 037 if given w/in 3d) https://t.co/aCTX7xFewW https://t.co/xbBeED9K7U

Australian CRISTAL RCT 23 458 OA adults undergoing hip or knee replacements & given ASA 100 mg/d or SC enoxaparin 40 mg qd for 35 days (THR) or 14 days(TKR) for VTE prophylaxis = no difference betw groups: 90D mortality was 1.67% vs 1.53% https://t.co/wBLtlyCcsF https://t.co/WFkZ2KNHFF